Navigation Links
Bronchitol Cystic Fibrosis Dose Trial Results Positive
Date:8/11/2008

itionally, no serious adverse events emerged during the 400 mg treatment period and the adverse event profile was similar across all doses.

People affected by cystic fibrosis typically experience a decline in lung function of 1-2% per year during their life, as measured by FEV1.

Pharmaxis has received Orphan Drug Designation and fast track status from the Food and Drug Administration (FDA) for Bronchitol in cystic fibrosis.

Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. Additional data from this trial will be presented at a forthcoming scientific congress. A European, Pharmaxis sponsored, regulatory Phase III clinical trial, designed to lead to a marketing application for Bronchitol in adults and children with cystic fibrosis is due to report preliminary data early in 2009.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.

To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .

About the Trial

The following information is provided in accord with the ASX and AusBiotech Code of Best Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.

Name of Trial DPM-CF-202 (a Phase II study with Bronchitol)

Blinding Status Open

Design Crossover, Dose response

Treatment Route Inhalation

Frequency Twice daily

Dose levels 400mg, 240 mg, 120 mg, 40 mg for 2 weeks,

1-2 weeks washout between doses

No of subjects PP population 38

Subject Selection diagnosis of cystic fibrosis (sweat test or

Criteria genotype), of either gender, aged 7 years or


'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Promising Cystic Fibrosis Compound on Track for Development
5. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 Regeneron Pharmaceuticals, ... the Proceedings of the National Academy of ... that the Company,s proprietary VelociGene ® and ... and preclinical validation of potential candidates that could ... Middle East Respiratory Syndrome (MERS). This involved the ...
(Date:6/29/2015)... Henry Schein , Inc. (NASDAQ: ... care products and services to office-based dental, animal ... has been selected as the Corporation of the ... (AHHE), a national voluntary tax-exempt organization that fosters ... Hispanic health care executives. The Company ...
(Date:6/29/2015)... 29, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... to the Russell 2000® Small Cap, Russell 3000®, and ... at the close of trading on June 26, 2015 ... of U.S. and global indexes. Sorrento is already a ... About the Russell Indexes. Russell indexes ...
Breaking Medicine Technology:Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 2Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 4Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 5Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 2Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 3Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 4Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 5Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 6Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes 2Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes 3
... China, May 26, 2011 /PRNewswire-Asia/ -- Winner Medical Group ... "the Company"), a leading manufacturer of medical dressings, medical ... products in China, today announced the resignation of one ... personal reasons. Winner Medical,s Board of Directors voted to ...
... 26, 2011 Reportlinker.com announces that a ... its catalogue: Specialty Pharmaceutical ... http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Specialty Pharmaceutical ... Summary GBI Research,s "Specialty ...
Cached Medicine Technology:Winner Medical Appoints New Independent Director 2Winner Medical Appoints New Independent Director 3Winner Medical Appoints New Independent Director 4Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 2Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 4Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 5Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 6Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 7Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 8Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 9Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 10Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 11Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 12Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 13Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 14Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 15Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 16
(Date:6/29/2015)... ... June 29, 2015 , ... ... within the weekend edition of USA TODAY. This 12-page, glossy, full-color special section ... Today in highly targeted markets totaling approximately 450,000 copies, with an estimated readership ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... “Lake Balboa Care Center”, showcasing its prestigious five-star, premium rating from Medicare. Medicare’s ... Lake Balboa views this rating as indicative of its commitment to providing patients ...
(Date:6/29/2015)... ... June 29, 2015 , ... A state-of-the-art implant designed ... Medical Center. The device is the first of its kind approved by the ... pressure (CPAP), the current standard of care for OSA. , Some 18 million ...
(Date:6/29/2015)... ... June 29, 2015 , ... World Patent Marketing, ... Diaper, a baby invention that makes parenthood less tiring without sacrificing your child's ... market value of USD 52.2 billion in 2017," says Scott Cooper, CEO and ...
(Date:6/29/2015)... ... 29, 2015 , ... National HealthCare Associates recently released a ... the 40-center nursing home group. Sixteen of their centers were rated “Best in ... in one or more customer service areas. Those centers received the prestigious “Customer ...
Breaking Medicine News(10 mins):Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:Lake Balboa Releases New Facility Video of Patient Testimonials 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4
... by pain, swelling, loose teeth and exposed bone , , ... people taking widely prescribed oral osteoporosis drugs who develop ... previously thought, a new study suggests. , Previous ... of the jaw (ONJ) from bisphosphonates in pill form ...
... scientists has discovered a new syndrome associated with severe ... lack sufficient infection-fighting white cells, and identified the genetic ... catalytic subunit 3 (G6PC3). The findings, which are published ... New England Journal of Medicine , were made by ...
... Of Southern California, School Of Dentistry release results of ... necrosis. The study is among the first to acknowledge ... may leave the jaw vulnerable to devastating necrosis, according ... Journal of the American Dental Association ( JADA ...
... in study participants , , WEDNESDAY, Dec. 31 (HealthDay News) ... its anti-inflammatory and pain-relieving properties, may be something humans ... , Salicylic acid (SA) previously had been found in ... recently -- especially vegetarians. This made sense because ...
... Minn. A new study shows that people who are smokers ... significantly more likely to suffer a stroke from a brain aneurysm ... issue of Neurology , the medical journal of the American ... print issue of Neurology . , The type of stroke, ...
... Priority in 2009SPRINGFIELD, Ill., Dec. 31 The following is ... Illinois:The economic situation is forcing more Illinois families to face ... of people are cutting back on necessities in order to ... it,s too expensive. High health care costs are leaving ...
Cached Medicine News:Health News:Study Links Osteoporosis Drugs to Jaw Trouble 2Health News:Study Links Osteoporosis Drugs to Jaw Trouble 3Health News:Scientists identify new congenital neutropenia syndrome and causative gene mutation 2Health News:Scientists identify new congenital neutropenia syndrome and causative gene mutation 3Health News:USC dentist links Fosomax-type drugs to jaw necrosis 2Health News:Smokers with stroke in the family 6 times more likely to have stroke too 2
... calibration mass for convenient Touch-key ... Fully Automatic Self-Calibration at designated ... are detected, or touch-key calibration ... Interface, Shimadzu WindowsDirect communication function. ...
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Do More with your Workforce. Technology That Makes Walkaway Automation a Reality. Engineered for Accurate Results. Multiple Levels of Control Reduce Contamination. Flexible Sample Preparation Platfor...
... The 3100 system offers continuous, unattended ... injection, separation and detection, and data ... autosampler and importing sample information, the ... "Start Run command. The instrument requires ...
Medicine Products: